Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — H1 2021 Earnings Presentation
33 slides from Pt Prodia Widyahusada Tbk's earnings presentation, 2021
Slide 1: 1H2021 Results Update
1H2021 Results Update
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: List of Figures
List of Figures Corporate Overview 04 Near Term and Long Term Strategy 18 Company Highlight 05 Network Expansion Plan 19 Financial Update 29 Company History 06 Leader in Next Gen Technology 20 Gross Profit and Net Income 30 Market Overview 07 Business Update 21 COGS and OPEX 31 Economy Outlook 08 Re
Slide 4: Corporate Overview
Corporate Overview 1
Slide 5: Company Highlight
IDR 1.24 Trillion • Established in 1973 with strong track record for more than 48 years experiences in 1H2021 Revenue (+88.4% yoy) Clinical Lab Industry • Pioneer and the leading clinical laboratory >1.6 Million testing Company with the most recognized Brand in Indonesia Patient Visits in 1H2021 (+7
Slide 6: Strong Track Record in Clinical Laboratory Testing
Strong Track Record in Clinical Laboratory Testing Received SMK3 accreditation and OHSAS The first private lab in Indonesia that Established professional Established 2015, along with the Award using fully automated Cobas 6800 for management team Prodia ChildLab as "Diagnostic Services RT-PCR
Slide 7: Market Overview
Market Overview 2
Slide 8: Indonesia Economic Outlook
Indonesia Economic Outlook 3.7% – 4.7% Indonesia’s GDP Growth Projection for 2021 Indonesia’s economic recovery and improvement in 2021 GDP Growth Projection 2021 will be supported by the Indonesia World effectiveness of Indonesia’s Govt’ 3.7% - 4.5% N/A COVID-19 pandemic World Bank 4.4% 5.6% contai
Slide 9: Investment Highlight
Investment Highlight 3
Slide 10: Largest Network & Market Share in Independent Clinical Lab Industry
Largest Network & Market Share in Independent Clinical Lab Industry Market Share by Revenue Prodia vs Total Independent Labs Independent Clinical Labs (2019 & 2020) (Billion IDR) 3YRS CAGR 7.4% 39.2% 39.5% 4,874 3YRS CAGR 4,551 4,222 8.2% 26.9% 2019 27.8% 2020 1,600 1,744 1,873 33.9% 32.7% 2018 2019
Slide 11: Strong Operational Track Record
Strong Operational Track Record VISITS REVENUE CAGR CAGR 5.4% 8.4% Prodia has generated continuous revenue growth 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 and increasing number of visits that supported REVENUE PER VISIT Company’s profitability EBITDA CAGR 2.8% CAGR 21.5% 2016 2017 2018 2019
Slide 12: Comprehensive Service Offering with Multiple Customer Segments
Comprehensive Service Offering with Multiple Customer Segments Routine Testing Non-Laboratory Testing Specialty Clinics One-stop shop, offering the most Esoteric Testing Referral Lab Services Doctor Consultation comprehensive Predictive, Preventive, General Medical Preventive Treatment range of clin
Slide 13: Scalable Hub and Spoke Business Model
Scalable Hub and Spoke Business Model 4 Referral Labs in Jakarta, Surabaya, Medan, Makassar Significant Economies of Scale Achieved “Hub and spoke” model Centralized information Prodia Clinical Labs, offers scalable platform Prodia Referral with integrated IT Hospitals and Other Clinics platform tha
Slide 14: Strong Relationship with Medical Community
Strong Relationship with Medical Community Strong relationships through the work of more Introduced new tests, such as NIPT ProSafe, Amino Acid Profile, than 500 Marketing and Laboratory Fatty Acid Profile, CArisk, DIArisk, Liquid biopsy EGFR Mutation, New Information Service personnel Born Screenin
Slide 15: Experienced Senior Leadership and Management Team
Experienced Senior Leadership and Management Team Professional Management Team with Strong Track Record in Delivering Superior Growth and Innovation Years of Years of Years of Years of Years of 48 Experience 48 Experience 38 Experience 30 Experience 30 Experience Andi Gunawan Endang Kemal Imam Keri
Slide 16: Shareholder Composition
Shareholder Composition PT Prodia Utama Bio Majesty Pte. Ltd. Public 57% 18% 25% Contract Research, therapy Distributor for Research and banking of healthcare Organization stem cell products PT Prodia Widyahusada Tbk Occupational In Vitro Health Diagnostics Nationwide Outlet Network across Indonesia
Slide 17: Growth Strategy
Growth Strategy 4
Slide 18: Growth Strategy
Growth Strategy Strengthen digital capabilities to Expand our presence and enable business growth grow our network of outlets in both physical and digital Develop data & analytics channel in Indonesia Near- capabilities to create business values A term Upgrade existing clinical Enhance internal oper
Slide 19: Prodia's Network Expansion Plan 2016 - 2021
Prodia’s Network Expansion Plan 2016 - 2021 1 2 3 4 5 Expand Network Upgrade Enhance Focus on Digital Service of Outlets Clinical Labs Operating Quality Development 31 regional referral labs Upgrade up to 39 Efficiency Mobile apps and clinical labs to PHC3 Clinics other digital services Up to 33 add
Slide 20: Leader in Next Generation Technology
Leader in Next Generation Technology Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Separation Next Generation Diagnostic Science Laboratory Laboratory Laboratory Anatomical Advance Pathology Immunology Laboratory Laboratory Personalized Treatment The Concept of Precision Me
Slide 21: Business Update
Business Update 5
Slide 22: Response to COVID-19 Pandemic
Response to COVID-19 Pandemic Develop COVID-19 Related Test: RT-PCR, Antibody, Antigen testing Expand More Collaboration and Partnership: More Hospital Referral especially for COVID-19 test and for Swab Sampling Create New Ways of Service: Cleanliness, Safety, Convenience Revisit Budget and Strategy
Slide 23: Deliver Solution for Customer Needs
DELIVER SOLUTION FOR CUSTOMER NEEDS Respond to People Behavior Changing and Customer’s Voice Services & Lab Online Marketing Product Lab Testing in Facilities and Education Innovation COVID-19 Pandemic Activities • Prodia Mobile • Digital • Complete Testing from • COVID-19 Testing • Home/Office Serv
Slide 24: Digital Transformation to Fulfill Customer Needs
Digital Transformation to Fulfill Customer Needs > > Prodia has enhanced its digital platform services New Prodia Mobile Ver. 3 – Launched in Jan 2021 24
Slide 25: Customer Centric Model
Customer Centric Model eRegistration New Innovation & Enhancement Prodia in your Car Service Prodia Home Customer Service Centric Tele-Consultation Tele-Radiology • General Practitioners • Clinical Pathologists Tele-Health* • Internist • Clinical Nutritionist • Sport Medicine 25
Slide 26: Outlet Development
Outlet Development 2021 Outlet 2016-2021 Outlet Development Development Target 259 292 287 267 263 1-2 20 283 Clinical Labs POC Outlets 5 7 4** 4** 2 4** 11 14 14 12 9 10 Total Outlet 130 128 122 103 101 1-2 1 118 Specialty Clinics Hospital Lab Hospital Labs Specialty Clinic 129 136 143 147* 148* 14
Slide 27: 7 New Tests Launched in 1H2021
Predictive, Preventive & Screening Targeted Diagnostic Pharmacogenomics Therapy 1. NIPT (ProSafe) 26. ADMA/SDMA 32. Jak2 Mutation 47.Jak 2 Mutation 57. Warfarin Indiv Test 2. Telomere Analysis 27. Prodia Skin and 33. Kidney Stone Analysis (FTIR) 48. Mutation EGFR (CYP2C9 & VCORC1 3. Vitamin A & E Ha
Slide 28: 1H2021 Revenue
1H2021 Revenue Quarterly Revenue Revenue (Unaudited) (Unaudited) in IDR Billion in IDR Billion FY16-FY20 CAGR +8.4% 1H17-1H21 CAGR +16.5% 2021 2020 2019 2018 2017 2016 • Revenue grew sharply by +88.4% in 1Q21, 4Q20, 1H21 yoy, mostly 625.5 671.3 1,873.4 1H20-1H21 driven by walk in, 1,744.3 growth: +8
Slide 29: Financial Update
Financial Update 6
Slide 30: 1H2021 Gross Profit & Net Income (Unaudited)
1H2021 Gross Profit & Net Income (Unaudited) Gross Profit (in IDR Billion) Net Income (in IDR Billion) FY17-FY20 CAGR +7.0% 1H17-1H21 CAGR +18.7% FY17-FY20 CAGR +21.2% 1H17-1H21 CAGR +50.5% 1H20-1H21 1H20-1H21 growth +127.0% growth +2,588.9% 1,041.0 1,046.2 942.8 301.0 853.5 268.7 766.9 210.3 150.8
Slide 31: 1H2021 COGS & OPEX (Unaudited)
1H2021 COGS & OPEX (Unaudited) COGS (in IDR Billion) OPEX (in IDR Billion) FY16-FY20 CAGR+10.0% 1H17-1H21 CAGR+13.3% FY16-FY20 CAGR +3.3% 1H17-1H21 CAGR +4.1% 0 1H20-1H21 1,000 110.0% 827.2 827 1H20-1H21 growth +47.6% 80.0% 770 713 746 growth +7.1% 0 703.3 800 676 50 656.9 46 90.0% 565.0 612.5 125 7
Slide 32: 1H2021 Financial Summary (Unaudited)
1H2021 Financial Summary (Unaudited) (in IDR Bn) 1H2021 1H2020 Change (in IDR Bn) 1H2021 1H2020 Change Revenue 1,238.4 657.3 +88.4% Total Asset 2,391.8 1,881.4 +27.1% Total Equity 1,928.8 1,534.3 +25.7% Gross Profit 766.9 337.8 +127.0% EBIT 365.5 -36.9 +1091.2% EBT 381.2 -16.8 +2368.5% Net Income 30
Slide 33: Thank You!
Thank You! For more information : PT Prodia Widyahusada Tbk investor.relation@prodia.co.id Prodia Tower, Jl. Kramat Raya No. 150, Jakarta 10430, Indonesia Phone +6221-3144182 ext. 3774, 3775 www.prodia.co.id 33
PT Prodia Widyahusada — H1 2021 Earnings Presentation on 6ix